Lineage Cell Therapeutics, Inc. (DE:BT3)

XASE:BT3

BT3

Lineage Therap

RESEARCH TOOLSreports

Lineage Therap (BT3) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BT3 Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Lineage

Therap

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BT3 Stock 12 Month Forecast

Average Price Target

€5.37

▲(298.01% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Lineage Therap in the last 3 months. The average price target is €5.37 with a high forecast of €7.74 and a low forecast of €2.58. The average price target represents a 298.01% change from the last price of €1.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","-1":"-€1","1.25":"€1.25","3.5":"€3.5","5.75":"€5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.73730972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.37313175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.57910324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.6197930553846156,2.129586110769231,2.639379166153846,3.1491722215384614,3.6589652769230767,4.168758332307693,4.678551387692308,5.188344443076923,5.698137498461539,6.207930553846154,6.717723609230769,7.2275166646153854,{"y":7.73730972,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.4379332115384615,1.7658664230769232,2.093799634615385,2.421732846153846,2.7496660576923073,3.0775992692307694,3.4055324807692307,3.733465692307692,4.061398903846154,4.389332115384615,4.717265326923076,5.0451985384615385,{"y":5.37313175,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.2230079415384616,1.336015883076923,1.4490238246153846,1.562031766153846,1.6750397076923078,1.7880476492307693,1.9010555907692308,2.0140635323076923,2.127071473846154,2.2400794153846153,2.353087356923077,2.4660952984615383,{"y":2.57910324,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.755,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.865,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€7.74

Average Price Target€5.37

Lowest Price Target€2.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Pantginis

H.C. Wainwright

€7.74

Buy

473.13%

Upside

Reiterated

05/26/26

H.C. Wainwright Reaffirms Their Buy Rating on Lineage Therap (LCTX)

Michael Okunewitch

Maxim Group

€2.58

Buy

91.04%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Lineage Therap (NYSE MKT: LCTX) and RenovoRx (NASDAQ: RNXT)

John Newman

Canaccord Genuity

€7.74

Buy

473.13%

Upside

Reiterated

05/13/26

Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)

Mayank Mamtani

B. Riley Securities

€2.58→€3.44

Buy

154.73%

Upside

Reiterated

03/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Albert Lowe

Craig-Hallum

€2.58

Buy

91.04%

Upside

Reiterated

11/25/25

Lineage Therap (LCTX) Gets a Buy from Craig-Hallum

Jack Allen

Robert W. Baird

€4.3

Buy

218.41%

Upside

Reiterated

09/23/25

Robert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Pantginis

H.C. Wainwright

€7.74

Buy

473.13%

Upside

Reiterated

05/26/26

H.C. Wainwright Reaffirms Their Buy Rating on Lineage Therap (LCTX)

Michael Okunewitch

Maxim Group

€2.58

Buy

91.04%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Lineage Therap (NYSE MKT: LCTX) and RenovoRx (NASDAQ: RNXT)

John Newman

Canaccord Genuity

€7.74

Buy

473.13%

Upside

Reiterated

05/13/26

Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)

Mayank Mamtani

B. Riley Securities

€2.58→€3.44

Buy

154.73%

Upside

Reiterated

03/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Albert Lowe

Craig-Hallum

€2.58

Buy

91.04%

Upside

Reiterated

11/25/25

Lineage Therap (LCTX) Gets a Buy from Craig-Hallum

Jack Allen

Robert W. Baird

€4.3

Buy

218.41%

Upside

Reiterated

09/23/25

Robert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lineage Therap

3 Months

Michael OkunewitchMaxim Group

Success Rate

9/13 ratings generated profit

Average Return

+33.95%

Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +33.95% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

10/13 ratings generated profit

Average Return

+72.57%

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +72.57% per trade.

2 Years

Michael OkunewitchMaxim Group

Success Rate

11/13 ratings generated profit

Average Return

+63.67%

Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +63.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BT3 Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BT3 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BT3 average Analyst price target in the past 3 months is 5.37.

Each month's total comprises the sum of three months' worth of ratings.

BT3 Financial Forecast

BT3 Earnings Forecast

Next quarter’s earnings estimate for BT3 is -€0.02 with a range of -€0.03 to €0.02. The previous quarter’s EPS was -€0.03. BT3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BT3 has Performed in-line its overall industry.

BT3 Sales Forecast

Next quarter’s sales forecast for BT3 is €4.17M with a range of €1.49M to €14.08M. The previous quarter’s sales results were €1.49M. BT3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BT3 has Performed in-line its overall industry.

BT3 Stock Forecast FAQ

What is DE:BT3’s average 12-month price target, according to analysts?

Based on analyst ratings, Lineage Cell Therapeutics, Inc.’s 12-month average price target is 5.37.

What is DE:BT3’s upside potential, based on the analysts’ average price target?

Lineage Cell Therapeutics, Inc. has 298.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Lineage Cell Therapeutics, Inc. a Buy, Sell or Hold?

Lineage Cell Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Lineage Cell Therapeutics, Inc.’s share price target?

The average share price target for Lineage Cell Therapeutics, Inc. is 5.37. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €7.74 ,and the lowest forecast is €2.58. The average share price target represents 298.01% Increase from the current price of €1.35.

What do analysts say about Lineage Cell Therapeutics, Inc.?

Lineage Cell Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Lineage Cell Therapeutics, Inc.?

To buy shares of DE:BT3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Lineage Therap (BT3) Stock Forecast & Price Target

BT3 Analyst Ratings

BT3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Lineage Therap

BT3 Analyst Recommendation Trends

BT3 Financial Forecast

BT3 Earnings Forecast

BT3 Sales Forecast

BT3 Stock Forecast FAQ

Detailed List of Analyst Forecasts